查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1869648

寻常型天疱疮市场规模、份额和趋势分析报告：按治疗类型、分销管道、地区和细分市场预测（2025-2033 年）

Pemphigus Vulgaris Market Size, Share & Trends Analysis Report By Therapy Type, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

寻常型天疱疮市场摘要

2024年全球寻常型天疱疮市场规模估计为4.813亿美元，预计2033年将达到9.752亿美元。

预计从 2025 年到 2033 年，该市场将以 8.2% 的复合年增长率成长。诊断技术和早期检测的改进、治疗方法的进步以及研发投入的增加正在推动市场成长。

寻常型天疱疮是一种严重且严重的自体免疫水痘疾病，主要涉及皮肤和黏膜。它约占全球所有天疱疮病例的70%。据报道，其发生率因地区和种族而异，每年每百万人中新增病例数在0.5至50例之间。

世界各国政府和基金会已启动多项计划，为寻常型天疱疮（PV）患者提供支援。例如，2023年12月，美国天疱疮和类天疱疮基金会（PAN基金会）与国际天疱疮和类天疱疮基金会（IPPF）合作，为PV患者提供经济援助。符合资格的患者每年最多可获得6600美元，用于支付患者及其看护者的相关费用和支持服务。

目录

第一章调查方法和范围

第二章执行摘要

第三章 寻常型天疱疮市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析

第四章 寻常型天疱疮市场：依治疗类型分類的估算与趋势分析

  • 按治疗类型分類的市场份额，2024 年和 2033 年
  • 按治疗类型细分仪表板
  • 按治疗类型分類的市场规模、预测和趋势分析，2021-2033年
  • 抗CD20单株抗体（利Rituximab单抗）
  • 全身性皮质类固醇
  • 传统类固醇替代免疫抑制剂
  • 静脉注射免疫球蛋白（IVIG）－辅助性治疗
  • 局部治疗

第五章 寻常型天疱疮市场：按分销管道分類的估算和趋势分析

  • 按分销管道分類的市场份额，2024 年和 2033 年
  • 按分销管道细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析，2021-2033年
  • 医院药房
  • 零售药房
  • 其他的

第六章 寻常型天疱疮市场：区域估算与趋势分析

  • 2024 年及 2033 年区域市占率分析
  • 区域市场概览
  • 市场规模及预测趋势分析，2021-2033年
  • 北美洲
    • 按国家/地区划分，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分，2021-2033 年
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 按国家/地区划分，2021-2033 年
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分，2021-2033 年
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 按国家/地区划分，2021-2033 年
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争情势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • Genentech, Inc.
    • Pfizer Inc.
    • CELLTRION INC.
    • Amgen Inc.
    • Zenyaku Kogyo Co.
Product Code: GVR-4-68040-769-6

Pemphigus Vulgaris Market Summary

The global pemphigus vulgaris market size was estimated at USD 481.3 million in 2024 and is projected to reach USD 975.2 million by 2033, growing at a CAGR of 8.2% from 2025 to 2033. Improved diagnostics & early detection, advancements in treatment modalities, and increasing R&D investments drive market growth.

Pemphigus vulgaris is a rare, severe autoimmune blistering disease primarily affecting the skin and mucous membranes. It accounts for approximately 70% of all pemphigus cases globally. Reported incidence varies globally by geography and ethnicity, ranging from 0.5 to 50 new cases per million people yearly.

Governments and foundations worldwide have initiated several programs to support individuals suffering from PV. For instance, in December 2023, in the U.S., the PAN Foundation, in partnership with the International Pemphigus & Pemphigoid Foundation (IPPF), offered financial assistance to PV patients. Eligible individuals are provided up to USD 6,600 annually to cover expenses and support services for patients & their caregivers.

Global Pemphigus Vulgaris Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pemphigus vulgaris market report based on therapy type, distribution channel, and region:

  • Therapy Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Anti-CD20 monoclonal antibodies (rituximab)
  • Systemic corticosteroids
  • Conventional steroid-sparing immunosuppressants
  • Intravenous immunoglobulin (IVIG) - adjunct
  • Topical therapies
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy Type
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pemphigus Vulgaris Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Pemphigus Vulgaris Market: Therapy Type Business Analysis

  • 4.1. Therapy Type Market Share, 2024 & 2033
  • 4.2. Therapy Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy Type, 2021 to 2033 (USD Million)
  • 4.4. Anti-CD20 monoclonal antibodies (rituximab)
    • 4.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Systemic corticosteroids
    • 4.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Conventional steroid-sparing immunosuppressants
    • 4.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Intravenous immunoglobulin (IVIG) - adjunct
    • 4.7.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Topical therapies
    • 4.8.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pemphigus Vulgaris Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pemphigus Vulgaris Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 6.4. North America
    • 6.4.1. North America Pemphigus Vulgaris Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Reimbursement Framework
      • 6.4.2.4. U.S. Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Reimbursement Framework
      • 6.4.3.4. U.S. Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Reimbursement Framework
      • 6.4.4.4. Mexico Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Pemphigus Vulgaris Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Reimbursement Framework
      • 6.5.2.4. UK Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Reimbursement Framework
      • 6.5.3.4. Germany Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Reimbursement Framework
      • 6.5.4.4. France Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Reimbursement Framework
      • 6.5.5.4. Italy Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Reimbursement Framework
      • 6.5.6.4. Spain Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Reimbursement Framework
      • 6.5.7.4. Denmark Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Reimbursement Framework
      • 6.5.8.4. Sweden Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Reimbursement Framework
      • 6.5.9.4. Norway Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Pemphigus Vulgaris Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Reimbursement Framework
      • 6.6.2.4. Japan Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Reimbursement Framework
      • 6.6.3.4. China Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Reimbursement Framework
      • 6.6.4.4. India Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Reimbursement Framework
      • 6.6.5.4. Australia Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Reimbursement Framework
      • 6.6.6.4. South Korea Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Reimbursement Framework
      • 6.6.7.4. Thailand Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Pemphigus Vulgaris Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Reimbursement Framework
      • 6.7.2.4. Brazil Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Reimbursement Framework
      • 6.7.3.4. Argentina Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Pemphigus Vulgaris Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Reimbursement Framework
      • 6.8.2.4. South Africa Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Reimbursement Framework
      • 6.8.3.4. Saudi Arabia Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Reimbursement Framework
      • 6.8.4.4. UAE Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Reimbursement Framework
      • 6.8.5.4. Kuwait Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Genentech, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Pfizer Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. CELLTRION INC.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Amgen Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Zenyaku Kogyo Co.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global pemphigus vulgaris market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 5 Global pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6 North America pemphigus vulgaris market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 8 North America pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 US pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 10 US pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 Canada pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 12 Canada pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 Mexico pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 14 Mexico pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 Europe pemphigus vulgaris market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 17 Europe pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18 UK pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 19 UK pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Germany pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 21 Germany pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22 France pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 23 France pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 Italy pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 25 Italy pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26 Spain pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 27 Spain pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 Denmark pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 29 Denmark pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 Sweden pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 31 Sweden pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Norway pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 33 Norway pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific pemphigus vulgaris market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 Japan pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 38 Japan pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 China pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 40 China pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41 India pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 42 India pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43 Australia pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 44 Australia pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 South Korea pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 46 South Korea pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47 Thailand pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 48 Thailand pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49 Latin America pemphigus vulgaris market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 51 Latin America pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Brazil pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 53 Brazil pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Argentina pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 55 Argentina pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa pemphigus vulgaris market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 South Africa pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 60 South Africa pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63 UAE pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 64 UAE pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Kuwait pemphigus vulgaris market, by therapy type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait pemphigus vulgaris market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Pemphigus vulgaris market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Pemphigus vulgaris market dynamics
  • Fig. 12 Pemphigus vulgaris market: Porter's five forces analysis
  • Fig. 13 Pemphigus vulgaris market: PESTLE analysis
  • Fig. 14 Pemphigus vulgaris market: Therapy type movement analysis
  • Fig. 15 Pemphigus vulgaris market: Therapy type outlook and key takeaways
  • Fig. 16 Anti-CD20 monoclonal antibodies (rituximab) market estimates and forecast, 2021 - 2033
  • Fig. 17 Systemic corticosteroids market estimates and forecast, 2021 - 2033
  • Fig. 18 Conventional steroid-sparing immunosuppressants market estimates and forecast, 2021 - 2033
  • Fig. 19 Intravenous immunoglobulin (IVIG) - adjunct market estimates and forecast, 2021 - 2033
  • Fig. 20 Topical therapies market estimates and forecast, 2021 - 2033
  • Fig. 21 Pemphigus vulgaris market: Distribution channel movement analysis
  • Fig. 22 Pemphigus vulgaris market: Distribution channel outlook and key takeaways
  • Fig. 23 Hospital Pharmacies market estimates and forecast, 2021 - 2033
  • Fig. 24 Retail pharmacies market estimates and forecast, 2021 - 2033
  • Fig. 25 OtherOthers market estimates and forecast, 2021 - 2033
  • Fig. 26 Pemphigus vulgaris market: Regional movement analysis
  • Fig. 27 Pemphigus vulgaris market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecast, 2021 - 2033
  • Fig. 29 U.S. market estimates and forecast, 2021 - 2033
  • Fig. 30 Canada market estimates and forecast, 2021 - 2033
  • Fig. 31 Mexico market estimates and forecast, 2021 - 2033
  • Fig. 32 Europe market estimates and forecast, 2021 - 2033
  • Fig. 33 UK market estimates and forecast, 2021 - 2033
  • Fig. 34 Germany market estimates and forecast, 2021 - 2033
  • Fig. 35 France market estimates and forecast, 2021 - 2033
  • Fig. 36 Italy market estimates and forecast, 2021 - 2033
  • Fig. 37 Spain market estimates and forecast, 2021 - 2033
  • Fig. 38 Denmark market estimates and forecast, 2021 - 2033
  • Fig. 39 Sweden market estimates and forecast, 2021 - 2033
  • Fig. 40 Norway market estimates and forecast, 2021 - 2033
  • Fig. 41 Asia Pacific market estimates and forecast, 2021 - 2033
  • Fig. 42 Japan market estimates and forecast, 2021 - 2033
  • Fig. 43 China market estimates and forecast, 2021 - 2033
  • Fig. 44 India market estimates and forecast, 2021 - 2033
  • Fig. 45 Australia market estimates and forecast, 2021 - 2033
  • Fig. 46 South Korea market estimates and forecast, 2021 - 2033
  • Fig. 47 Thailand market estimates and forecast, 2021 - 2033
  • Fig. 48 Latin America market estimates and forecast, 2021 - 2033
  • Fig. 49 Brazil market estimates and forecast, 2021 - 2033
  • Fig. 50 Argentina market estimates and forecast, 2021 - 2033
  • Fig. 51 Middle East & Africa market estimates and forecast, 2021 - 2033
  • Fig. 52 South Africa market estimates and forecast, 2021 - 2033
  • Fig. 53 Saudi Arabia market estimates and forecast, 2021 - 2033
  • Fig. 54 UAE market estimates and forecast, 2021 - 2033
  • Fig. 55 Kuwait market estimates and forecast, 2021 - 2033
  • Fig. 56 Company categorization
  • Fig. 57 Company market position analysis
  • Fig. 58 Strategic framework